Cancer Vaccines Market Set to Grow Big by 2023
The global cancer vaccines market is projected to reach at $12,814 million by 2023, growing at a CAGR of 17.7%. The recombinant cancer vaccines segment accounted for one-third share of the global market in 2016.
The global cancer vaccines market is projected to reach at $12,814 million by 2023, growing at a CAGR of 17.7%. The recombinant cancer vaccines segment accounted for one-third share of the global market in 2016.
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
<strong>Cancer</strong> <strong>Vaccines</strong> <strong>Market</strong><br />
Opportunity Analysis and Industry Forecast, 2016-<strong>2023</strong><br />
Global<br />
Opportunity<br />
Analysis and<br />
Industry Forecast,<br />
2017-<strong>2023</strong>
Introductionof<br />
<strong>Cancer</strong> <strong>Vaccines</strong> <strong>Market</strong><br />
The global cancer vaccines market was valued at $4,073 million in 2016, and is<br />
projected <strong>to</strong> reach at $12,814 million <strong>by</strong> <strong>2023</strong>, growing at a CAGR of 17.7% from 2017<br />
<strong>to</strong> <strong>2023</strong>. The recombinant cancer vaccines segment accounted for one-third share of<br />
the global market in 2016.<br />
<strong>Vaccines</strong> include antigenic components, which strengthens an individuals immune<br />
system <strong>by</strong> developing adaptive immunity <strong>to</strong> prevent morbidity from infections. <strong>Cancer</strong><br />
vaccine is a type of immunotherapy that boost the bodys natural defenses <strong>by</strong><br />
stimulating the immune system <strong>to</strong> recognize and cure cancerous cells.<br />
The global market is driven <strong>by</strong> rise in prevalence of HPV infections and related cancer,<br />
increase in administration of prophylactic cancer vaccines, surge in investments &<br />
findings in the development of cancer vaccines, and launch of novel cancer vaccines in<br />
the market. However, longer timelines required for manufacturing a single vaccine<br />
restrain the development of new vaccines; there<strong>by</strong>, hampering the market growth. In<br />
addition, high monetary inputs for the development of cancer vaccines decrease their<br />
adoption in the market; there<strong>by</strong>, hampering the market growth.
Introductionof<br />
<strong>Cancer</strong> <strong>Vaccines</strong> <strong>Market</strong><br />
Scope of the Report<br />
Key Benefits<br />
Key Audiences
Key Benefits<br />
• The dendritic cells cancer vaccines segment is anticipated <strong>to</strong> grow at the highest rate<br />
during the forecast period.<br />
• The preventive cancer vaccines segment dominated the global market, accounting for fiveninths<br />
share of the global market in 2016.<br />
• North America dominated the global market, accounting for the maximum share of overall<br />
market in 2016, and is expected <strong>to</strong> continue this trend throughout the forecast period.<br />
• Asia-Pacific is exhibited <strong>to</strong> grow at a CAGR of 19.6% during the forecast period, owing <strong>to</strong><br />
the high demand for vaccination in densely populated countries, such as India and China.<br />
• The cervical cancer segment generated the highest revenue in 2016, and is expected <strong>to</strong><br />
continue its dominance in the near future.<br />
• The pediatric vaccines segment is expected <strong>to</strong> exhibit high growth rate during forecast<br />
period, owing <strong>to</strong> the increase in demand for preventive cancer vaccines.
Table of Content (TOC)<br />
Chapter: 1 Introduction<br />
Chapter: 2 Executive Summary<br />
Chapter: 3 <strong>Market</strong> Overview<br />
Chapter: 4 <strong>Cancer</strong> <strong>Vaccines</strong> <strong>Market</strong>, By Technology<br />
Chapter: 5 <strong>Cancer</strong> <strong>Vaccines</strong> <strong>Market</strong>, By Type<br />
Chapter: 6 <strong>Cancer</strong> <strong>Vaccines</strong>, By Indication<br />
Chapter: 7 <strong>Cancer</strong> <strong>Vaccines</strong> <strong>Market</strong>, By End Use<br />
Chapter: 8 Company Profiles
Segments<br />
<strong>Cancer</strong> <strong>Vaccines</strong> <strong>Market</strong>
Segments<br />
<strong>Cancer</strong> <strong>Vaccines</strong> <strong>Market</strong>
Segments<br />
<strong>Cancer</strong> <strong>Vaccines</strong> <strong>Market</strong>
Company Profiles<br />
<strong>Cancer</strong> <strong>Vaccines</strong> <strong>Market</strong><br />
1. ASTRAZENECA PLC. (MEDIMMUNE, LLC.)<br />
2. GLAXOSMITHKLINE PLC.<br />
3. MERCK & CO., INC.<br />
4. SANOFI PASTEUR<br />
5. ADURO BIOTECH INC.<br />
6. SANPOWER GROUP CO., LTD.
Thank You<br />
<strong>Cancer</strong> <strong>Vaccines</strong> <strong>Market</strong><br />
ThankYou!<br />
For More Details<br />
Do Enquiry<br />
https://www.alliedmarketresearch.com/cancer-vaccines-market<br />
Follow Us On
Change language